100% satisfaction guarantee Immediately available after payment Both online and in PDF No strings attached
logo-home
Previously searched by you
Previously searched by you
logo
Samenvatting prof Laleman spijsvertering $8.13
Add to cart
Quickly navigate to
Preview
  2.  
  3. Katholieke Universiteit Leuven (KU Leuven)
  4.  
  5. Geneeskunde
  6.  
  7. Spijsvertering (E0C09A)

Summary

Samenvatting prof Laleman spijsvertering

 2 views  0 purchase
  • Course
  • Spijsvertering (E0C09A)
  • Institution
  • Katholieke Universiteit Leuven (KU Leuven)
  • Book
  • Aandoeningen van het spijsverteringsstelsel

Samenvatting vak Spijsvertering, gegeven in 1e master GNK. Volledige samenvatting van powerpoint, collegenotities en boek. Deel gegeven door Prof. Dr. Wim Laleman.

Preview 4 out of 79  pages

Document information

  • No
  • 7-8
  • January 5, 2025
  • 79
  • 2024/2025
  • Summary

Subjects

  • spijsvertering
  • 1e master gnk
  • hematologie
  • pancreas

Connected book

book image

Book Title:

Author(s):

  • Edition:
  • ISBN:
  • Edition:

Written for

  • Katholieke Universiteit Leuven (KU Leuven)
  • Geneeskunde
  • Spijsvertering (E0C09A)
All documents for this subject (78)

Seller

avatar-seller
jozefienceulemans

Content preview

2024-
2025




Hepatologie en
beningne aandoeningen
van de pancreas
PROF DR LALEMAN
JOZEFIEN CEULEMANS

,Lever-, gal-, en pancreasaandoeningen: inleiding + acute leverziekten .............................. 6
Inleiding ................................................................................................................................... 6
Anatomie lever .............................................................................................................................................. 6
Galwegen .................................................................................................................................................. 6
Fysiologie lever .............................................................................................................................................. 6
Synthese.................................................................................................................................................... 7
Afbraak...................................................................................................................................................... 7
Stockeren .................................................................................................................................................. 7
Immunologie ............................................................................................................................................. 7
Functie van gal .......................................................................................................................................... 8
Hoe schade inschatten en evalueren ............................................................................................................ 8
Klinisch onderzoek .................................................................................................................................... 8
Lever-testen .............................................................................................................................................. 8
Afwijkende levertesten ........................................................................................................................... 10
Technische onderzoeken/interventies ................................................................................................... 10
Acute hepatitis ....................................................................................................................... 11
Definitie ....................................................................................................................................................... 11
Kliniek .......................................................................................................................................................... 12
Algemene biochemische kenmerken .......................................................................................................... 12
Etiologie ....................................................................................................................................................... 12
Specifieke vormen ....................................................................................................................................... 12
Infectieus – virale hepatitis ..................................................................................................................... 12
Niet-virale hepatitis ................................................................................................................................ 16
Specifieke vormen/ diagnostiek .................................................................................................................. 17
Toxisch leverlijden .................................................................................................................................. 17
Andere .................................................................................................................................................... 18
Complicatie: acuut leverfalen ...................................................................................................................... 18
Definitie acuut leverfalen ....................................................................................................................... 18
Criteria lever tx ....................................................................................................................................... 19

Chronische leverziekten .................................................................................................. 19
Definitie en relevantie ............................................................................................................ 19
Definitie ....................................................................................................................................................... 19
Relevantie .................................................................................................................................................... 19
Schade/fibrose evalueren ....................................................................................................... 19
Kliniek.................................................................................................................................... 20
Etiologie - DD/........................................................................................................................ 20
Bespreking specifieke vormen ................................................................................................ 20
Infectieuze vormen ...................................................................................................................................... 20
Hepatitis B............................................................................................................................................... 20
Chronische hepatitis D ............................................................................................................................ 22
Chronische hepatitis C ............................................................................................................................ 23
Chronische hepatitis E ............................................................................................................................ 23
Chronisch auto-immune hepatitis ............................................................................................................... 23
Definitie en pathofysiologie .................................................................................................................... 23
Kliniek ..................................................................................................................................................... 23
Diagnose ................................................................................................................................................. 24
Behandeling en prognose ....................................................................................................................... 24
Cholestatische leverziekten .................................................................................................... 24
Vocabularium .............................................................................................................................................. 24
Onstaan ................................................................................................................................................... 25
Primaire biliaire cholangitis ......................................................................................................................... 25



1

, Definitie en pathogenese ........................................................................................................................ 25
Symptomatologie .................................................................................................................................... 26
Epidemiologie en natuurlijk verloop ....................................................................................................... 26
Klinisch beeld .......................................................................................................................................... 26
Diagnose ................................................................................................................................................. 26
Prognose ................................................................................................................................................. 27
Behandeling ............................................................................................................................................ 27
Primaire scleroserende cholangitis ............................................................................................................. 28
Definitie en pathogenese ........................................................................................................................ 28
Kliniek ..................................................................................................................................................... 28
Complicaties............................................................................................................................................ 28
Diagnose ................................................................................................................................................. 29
Behandeling ............................................................................................................................................ 29
IgG4- geassocieerde cholangiopathie .......................................................................................................... 29
Metabole aandoeningen......................................................................................................... 29
Hemochromatose ........................................................................................................................................ 29
Definitie .................................................................................................................................................. 29
Fe metabolisme ...................................................................................................................................... 29
Pathofysiologie ....................................................................................................................................... 30
Epidemiologie ......................................................................................................................................... 30
Klinisch beeld .......................................................................................................................................... 30
Diagnose ................................................................................................................................................. 30
Behandeling ............................................................................................................................................ 31
Screening ................................................................................................................................................ 31
Ziekte van Wilson ........................................................................................................................................ 31
Cu metabolisme ...................................................................................................................................... 31
Diagnose en behandeling ....................................................................................................................... 32
Alfa-1-antitrypsine (A1AT) ........................................................................................................................... 32
Normale rol ............................................................................................................................................. 32
Genotype bepaalt fenotype .................................................................................................................... 32
Diagnose ................................................................................................................................................. 32
Behandeling ............................................................................................................................................ 32
Zeldzame ziekte of weesziekten .................................................................................................................. 33
Porfyrie ................................................................................................................................................... 33
Steatotische leveraandoeningen ............................................................................................. 33
Definitie ....................................................................................................................................................... 33
MASLD ......................................................................................................................................................... 33
Definitie .................................................................................................................................................. 33
Epidemiologie ......................................................................................................................................... 33
Pathogenese ........................................................................................................................................... 33
Kliniek ..................................................................................................................................................... 34
Diagnose ................................................................................................................................................. 34
Behandeling ............................................................................................................................................ 35
ALD: alcohol-associated liver disease .......................................................................................................... 35
Definitie .................................................................................................................................................. 35
Alcohol use disorder: AUD ...................................................................................................................... 36
Epidemiologie ......................................................................................................................................... 36
Pathofysiologie ....................................................................................................................................... 36
Bevorderende factoren schade .............................................................................................................. 37
Klinisch spectrum .................................................................................................................................... 37
Behandeling ............................................................................................................................................ 37
Alcoholische steatohepatitis (ASH) ......................................................................................................... 38
MetALD ........................................................................................................................................................ 39
Specific Etilogie SLD ..................................................................................................................................... 39

Vasculaire aandoeningen van de lever ............................................................................ 40


2

, Ischemische hepatitis ............................................................................................................. 40
Definitie ....................................................................................................................................................... 40
Congestieve hepatopathie ...................................................................................................................... 40
Vena porta thrombose ........................................................................................................... 41
Definitie ....................................................................................................................................................... 41
Etiologie ....................................................................................................................................................... 41
Kliniek .......................................................................................................................................................... 41
Behandeling ................................................................................................................................................. 42
Primair voor trombose ............................................................................................................................ 42
Complicaties............................................................................................................................................ 42
Portale biliopathie ....................................................................................................................................... 42
Syndroom van Budd-Chiari (BCS) ............................................................................................ 42
Definitie ....................................................................................................................................................... 42
Kliniek .......................................................................................................................................................... 42
Oorzaken ..................................................................................................................................................... 43
Pathofysiologie ............................................................................................................................................ 43
Diagnose ...................................................................................................................................................... 43
Behandeling ................................................................................................................................................. 44
Sinusoidaal obstructie syndroom ............................................................................................ 44
Definitie ....................................................................................................................................................... 44
Ziekte van Rendu-Osler-Weber ............................................................................................... 44
Kliniek .......................................................................................................................................................... 45
Lever in HHT ............................................................................................................................................ 45
Behandeling ................................................................................................................................................. 45
Porto-Sinusoidal vascular disorder (PSVD)............................................................................... 45
Cirrose ............................................................................................................................ 46
Definitie en relevantie ............................................................................................................ 46
Pathogenese - Cirrogenese ..................................................................................................... 46
Natural history ....................................................................................................................... 47
Prognose & scores .................................................................................................................. 47
Cirrose “(h)erkennen” ............................................................................................................ 48
Kliniek .......................................................................................................................................................... 48
Technische onderzoeken ............................................................................................................................. 48
Algemene aanpak cirrose ....................................................................................................... 48
Complicaties gerelateerd aan portale hypertensie ................................................................... 49
Gastro-oesofageale varices ..................................................................................................................... 50
Ascites .......................................................................................................................................................... 53
Hepatopulmonaal syndroom en hypertensie .............................................................................................. 56
Complicaties gerelateerd aan leverinsufficiëntie ..................................................................... 56
Hepatische encephalopathie ....................................................................................................................... 56
Klinisch beeld .......................................................................................................................................... 56
Classificatie ............................................................................................................................................. 56
Aanpak .................................................................................................................................................... 58
Behandeling ............................................................................................................................................ 58
Complicatie: Acuut op chronisch leverfalen (ACLF) .................................................................. 59
Pathofysiologie ............................................................................................................................................ 59
Huidig beeld ................................................................................................................................................. 59




3

The benefits of buying summaries with Stuvia:

Guaranteed quality through customer reviews

Guaranteed quality through customer reviews

Stuvia customers have reviewed more than 700,000 summaries. This how you know that you are buying the best documents.

Quick and easy check-out

Quick and easy check-out

You can quickly pay through credit card or Stuvia-credit for the summaries. There is no membership needed.

Focus on what matters

Focus on what matters

Your fellow students write the study notes themselves, which is why the documents are always reliable and up-to-date. This ensures you quickly get to the core!

Frequently asked questions

What do I get when I buy this document?

You get a PDF, available immediately after your purchase. The purchased document is accessible anytime, anywhere and indefinitely through your profile.

Satisfaction guarantee: how does it work?

Our satisfaction guarantee ensures that you always find a study document that suits you well. You fill out a form, and our customer service team takes care of the rest.

Who am I buying these notes from?

Stuvia is a marketplace, so you are not buying this document from us, but from seller jozefienceulemans. Stuvia facilitates payment to the seller.

Will I be stuck with a subscription?

No, you only buy these notes for $8.13. You're not tied to anything after your purchase.

Can Stuvia be trusted?

4.6 stars on Google & Trustpilot (+1000 reviews)

51662 documents were sold in the last 30 days

Founded in 2010, the go-to place to buy study notes for 15 years now

Start selling
$8.13
  • (0)
Add to cart
Added